SUNPHARMA - Sun Pharmaceutical Industries Ltd. SUNPHARMA
After Q4 Results we saw a good sell-off in Sunpharma, yet the price hardly moved much
Shanghvi stated "Our India business continues to grow faster than the market, leading to an increase in market share. We continue to focus on expanding our global specialty business, growing all our businesses, and improving operational efficiencies," stated.
The company said its board has proposed a final dividend of Rs 3 per share for FY22.
One can plan a long position between 835 to 840 with a strict SL of Rs 825 for short term trading (01 to 02 weeks) and SL if the price moves below 825 (Daily candle close) for long term swing trading (greater than 2 weeks)
Short Term targets are up to - 886 Long Term Target is up to - 929